Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Approved Drugs for Infections and Infectious Diseases in Clinical Development in ISRAEL

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              RedHill Biopharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners

              Contact the Supplier

              Lead Product(s): Omeprazole Magnesium,Amoxycillin,Rifabutin

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: HealthCare Royalty Partners

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing February 25, 2020

              Details:

              The non-dilutive financing will support the acquisition of rights to Movantik® from AstraZeneca, the planned U.S. launch of Talicia® this quarter and the ongoing promotion of Aemcolo®.

              RedHill Biopharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®; Discontinuing Promotion of Legacy Products

              Contact the Supplier

              Lead Product(s): Omeprazole Magnesium,Amoxycillin,Rifabutin

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Entera Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Termination Agreement January 21, 2020

              Details:

              RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed.

              PharmaCompass__DigitalAd